Enject (United States)

Recent papers from Enject (United States)

1. Lipoxin A4 (LXA4) for diabetic retinopathy (DR)Indian Journal of Ophthalmology · 2026
2. Crosstalk between renin and arachidonic acid (and its metabolites)Lipids in Health and Disease · 2025
3. Syntaxin interacts with arachidonic acid to prevent diabetes mellitusLipids in Health and Disease · 2022
4. Molecular biochemical aspects of salt (sodium chloride) in inflammation and immune response with reference to hypertension and type 2 diabetes mellitusLipids in Health and Disease · 2021
5. Bioactive Lipids as Mediators of the Beneficial Action(s) of Mesenchymal Stem Cells in COVID-19Aging and Disease · 2020
6. PUFAs, BDNF and lipoxin A4 inhibit chemical-induced cytotoxicity of RIN5F cells in vitro and streptozotocin-induced type 2 diabetes mellitus in vivoLipids in Health and Disease · 2019
7. Dysregulation of PI3K-Akt-mTOR pathway in brain of streptozotocin-induced type 2 diabetes mellitus in Wistar ratsLipids in Health and Disease · 2018
8. n‐6 and n‐3 Fatty acids and their metabolites augment inhibitory action of doxorubicin on the proliferation of human neuroblastoma ( IMR ‐32) cells by enhancing lipid peroxidation and suppressing Ras, Myc, and FosBioFactors · 2018
9. Treating Severe HypoglycemiaJournal of Diabetes Science and Technology · 2014
10. Glucagon in the Artificial PancreasJournal of Diabetes Science and Technology · 2014